Unlocking The Potential of LYVE1: A Novel ELCP-1 as A Drug Target and Biomarker

Target Name: LYVE1

NCBI ID: G10894

LYVE1

Unlocking The Potential of LYVE1: A Novel ELCP-1 as A Drug Target and Biomarker

Unlocking the Potential of LYVE1: A novel Extracellular Link Domain-Containing Protein 1 (ELCP-1) as a Drug Target and Biomarker

Extracellular link domain-containing proteins (ELCPs) are a family of transmembrane proteins that play a crucial role in various cellular processes. ELCPPs are involved in various signaling pathways, including cell adhesion, migration, and invasion, and have been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, targeting ELCPs offers a new strategy for developing therapeutic approaches for these diseases. In this article, we focus on LYVE1, a novel ELCP-1 that has been shown to have unique functions and may serve as a potential drug target or biomarker.

LYVE1: A novel Extracellular Link Domain-Containing Protein 1

LYVE1, also known as ELCP-1, is a 21-kDa protein that is expressed in various tissues and cell types, including brain, pancreas, and muscle. It is a member of the ELCP family and is characterized by an extracellular domain that contains a unique open reading frame (ORF) that is enriched in the cytoplasm of the cell. LYVE1 is also known to have a unique N-terminal region that is rich in putative nuclear export signals and to be involved in the regulation of cellular processes, including cell adhesion and migration.

LYVE1 Functions and Potential Therapeutic Applications

The functions of LYVE1 are still being fully understood, but research has shown that it plays an important role in various cellular processes. One of its most well-studied functions is its role in cell adhesion. LYVE1 has been shown to be involved in the regulation of tight junction formation and cell-cell adhesion, which are critical for maintaining tissue structure and function.

In addition to its role in cell adhesion, LYVE1 has also been shown to be involved in the regulation of cell migration. LYVE1 has been shown to be involved in the regulation of cell migration in various tissues, including the brain (4) and pancreas.

The potential therapeutic applications of LYVE1 are vast, and research is ongoing to determine its potential as a drug target or biomarker. One approach that is being explored is the use of small molecules to inhibit the activity of LYVE1 and disrupt its functions. For example, recent studies have shown that inhibitors of LYVE1 can be effective in treating various diseases, including cancer and neurodegenerative diseases.

Conclusion

In conclusion, LYVE1 is a novel and promising protein that has unique functions and may serve as a potential drug target or biomarker. Its role in cell adhesion and migration makes it an attractive target for therapeutic approaches, and its unique N-terminal region makes it a promising candidate for biomarkers. Further research is needed to fully understand the functions of LYVE1 and its potential therapeutic applications.

Protein Name: Lymphatic Vessel Endothelial Hyaluronan Receptor 1

Functions: Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes (PubMed:10037799). Binds to pericelluar hyaluronan matrices deposited on the surface of leukocytes and facilitates cell adhesion and migration through lymphatic endothelium (PubMed:26823460)

The "LYVE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYVE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets